TY - JOUR T1 - Parents’ intention to vaccinate their 5-11 years old children with the COVID-19 vaccine: rates, predictors and the role of incentives JF - medRxiv DO - 10.1101/2021.11.05.21265900 SP - 2021.11.05.21265900 AU - Liora Shmueli Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/11/09/2021.11.05.21265900.abstract N2 - Background On September 20, 2021, Pfizer announced encouraging effectiveness and safety results from their COVID-19 vaccine clinical trials in 5-11 years old children. This study aims to assess parents’ perceptions and intention to vaccinate their 5-11 years old children and to determine the socio-demographic, health-related and behavioral factors, as well as the role of incentives beyond these factors, in predicting this intention.Methods A cross-sectional representative online survey among parents of children aged 5-11 years in Israel (n=1,012). The survey was carried out between September 23 and October 4, 2021, at a critical time, immediately after Pfizer’s announcement. Two multivariate regressions were performed to determine predictors of parents’ intention to vaccinate their 5-11 years old children against COVID-19 in the coming winter and how soon they intend to do so.Results Overall, 57% of the participants reported their intention to vaccinate their 5-11 years old children against COVID-19 in the coming winter. This intention was higher for participants over the age of 40. Perceived susceptibility, perceived benefits, perceived barriers, and cues to action, as well as two incentives - vaccine availability and receiving a ‘green pass’ - were all significant predictors of this intention. When asked about how soon they intend to vaccinate their 5-11 years old children, 27% of the participants responded immediately; 26% within three months; and 24% within more than three months. Participants having a family member suffering from a chronic disease as well as those whose children were vaccinated against influenza in the previous winter intend to vaccinate their children sooner. Perceived susceptibility, perceived severity, perceived benefits, perceived barriers, and cues to action, were all found to be significant predictors of this sense of urgency. Similar to the intention to vaccinate children in the coming winter, while vaccine availability and receiving a ‘green pass’ were found to be positive significant predictors of how soon parents intend to vaccinate their children, other incentives such as monetary rewards or monetary penalties were not found to be significant predictors. Parental concerns centered around the safety of the vaccine (64%), fear of severe side effects (60%), and fear that clinical trials and the authorization process were carried out too quickly (56%).Conclusions This study provides up-to-date information on the rates of the intention of parents to vaccinate their 5-11 years old children, how soon they intend to do so, and the predictors of those intentions, which is essential for health policy makers and healthcare providers for planning vaccination campaigns. Moreover, as vaccine safety and side effects were found to be key parental concerns, it is important to release post-approval safety data regarding the vaccine to the public as soon as such is available. Finally, our findings underscore the important role of vaccine accessibility and receiving a ‘green pass’ over other incentives in promoting parents’ intentions to vaccinate their children.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee for Non-clinical Studies at Bar-Ilan University in Israel. The ethics form was signed by the committee head on September 14, 2021.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during the current study are not publicly available but are available from the corresponding author on a reasonable request. ER -